Overview

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Status:
Completed

Trial end date:
2015-04-01

Target enrollment:

Participant gender:

Summary

This study is designed to determine the effectiveness of florbetapir (18F) in changing patient management and to evaluate the association between scan status and cognitive decline.

Phase:

Phase 4

Details

Lead Sponsor:

Avid Radiopharmaceuticals

Collaborator:

Eli Lilly and Company